Matches in SemOpenAlex for { <https://semopenalex.org/work/W868276148> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W868276148 endingPage "5237" @default.
- W868276148 startingPage "5237" @default.
- W868276148 abstract "Abstract ONC201/TIC10 is a potent small molecule anti-tumor agent in several types of solid tumors and lymphomas. ONC201/TIC10 is on track to enter clinical trials for patients with advanced cancer in 2014, with IND issued by the FDA in March, 2014. Early trials will evaluate the safety and efficacy of ONC201/TIC10 as a monoagent in hematological malignancies. In the current study, we evaluated the anti-cancer effects of the small molecule in Acute Lymphoblastic Leukemia (ALL). Analysis of cell viability by the CellTiter-Glo method revealed that ONC201/TIC10 treatment reduces the viability of three ALL cell lines (Reh, Jurkat, MOLT-4) in a dose- (2.5/5/10 μM) and time-dependent manner (24/48/72 h). We have previously reported that ONC201/TIC10-mediated reduction in cell viability and apoptosis in various types of solid tumors occurs at 60/72 h. Interestingly, ONC201/TIC10 reduces the viability of ALL cell lines within 24/48 h at the indicated doses. An inactive TIC10 isomer compound synthesized by Medkoo Biosciences with a structure related to the active ONC201/TIC10 compound does not reduce the viability of ALL cells. Sub-G1 analysis indicated that ONC201/TIC10 induces apoptosis in ALL cells and a pan-caspase inhibitor reduces ONC201/TIC10-mediated apoptosis. Western blot analysis was used to further investigate the mechanism of ONC201/TIC10-mediated apoptosis. ONC201/TIC10-mediated apoptosis involves PARP cleavage and caspase-9 activation. Anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xl are downregulated while the pro-apoptotic Bcl-2 family member Bim is upregulated in response to ONC201/TIC10 treatment. ONC201/TIC10 also downregulates the inhibitor of apoptosis (IAP) family proteins cIAP1 and cIAP2. We have previously shown that the anti-tumor effect of ONC201/TIC10 involves inhibition Akt and ERK phosphorylation resulting in Foxo3a activation and TRAIL-gene transcription. We observed inhibition of Akt phosphorylation upon ONC201/TIC10 treatment of ALL cells. Thus, ONC201/TIC10 holds promise as a novel agent for the treatment of ALL based on its robust activity in preclinical models of the disease. Our ongoing studies are evaluating the impact of this novel therapy on ALL cells with different translocations, and are introducing combination therapy with ONC201/TIC10 for ALL. Figure 1 Figure 1. Disclosures Allen: Oncoceutics: Employment, Equity Ownership, Patents & Royalties. El-Deiry:Oncoceutics, Inc.: Equity Ownership, Patents & Royalties." @default.
- W868276148 created "2016-06-24" @default.
- W868276148 creator A5004302802 @default.
- W868276148 creator A5007967797 @default.
- W868276148 creator A5008547275 @default.
- W868276148 creator A5023976873 @default.
- W868276148 creator A5026724096 @default.
- W868276148 creator A5028299420 @default.
- W868276148 creator A5034307197 @default.
- W868276148 creator A5039564965 @default.
- W868276148 creator A5040990076 @default.
- W868276148 creator A5056800304 @default.
- W868276148 creator A5075201353 @default.
- W868276148 creator A5083321772 @default.
- W868276148 date "2014-12-06" @default.
- W868276148 modified "2023-10-12" @default.
- W868276148 title "Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins" @default.
- W868276148 doi "https://doi.org/10.1182/blood.v124.21.5237.5237" @default.
- W868276148 hasPublicationYear "2014" @default.
- W868276148 type Work @default.
- W868276148 sameAs 868276148 @default.
- W868276148 citedByCount "1" @default.
- W868276148 countsByYear W8682761482016 @default.
- W868276148 crossrefType "journal-article" @default.
- W868276148 hasAuthorship W868276148A5004302802 @default.
- W868276148 hasAuthorship W868276148A5007967797 @default.
- W868276148 hasAuthorship W868276148A5008547275 @default.
- W868276148 hasAuthorship W868276148A5023976873 @default.
- W868276148 hasAuthorship W868276148A5026724096 @default.
- W868276148 hasAuthorship W868276148A5028299420 @default.
- W868276148 hasAuthorship W868276148A5034307197 @default.
- W868276148 hasAuthorship W868276148A5039564965 @default.
- W868276148 hasAuthorship W868276148A5040990076 @default.
- W868276148 hasAuthorship W868276148A5056800304 @default.
- W868276148 hasAuthorship W868276148A5075201353 @default.
- W868276148 hasAuthorship W868276148A5083321772 @default.
- W868276148 hasBestOaLocation W8682761481 @default.
- W868276148 hasConcept C153911025 @default.
- W868276148 hasConcept C179464577 @default.
- W868276148 hasConcept C185592680 @default.
- W868276148 hasConcept C190283241 @default.
- W868276148 hasConcept C203014093 @default.
- W868276148 hasConcept C2776090121 @default.
- W868276148 hasConcept C31573885 @default.
- W868276148 hasConcept C502942594 @default.
- W868276148 hasConcept C53227056 @default.
- W868276148 hasConcept C55493867 @default.
- W868276148 hasConcept C71924100 @default.
- W868276148 hasConcept C86803240 @default.
- W868276148 hasConcept C8891405 @default.
- W868276148 hasConcept C98274493 @default.
- W868276148 hasConcept C98424977 @default.
- W868276148 hasConceptScore W868276148C153911025 @default.
- W868276148 hasConceptScore W868276148C179464577 @default.
- W868276148 hasConceptScore W868276148C185592680 @default.
- W868276148 hasConceptScore W868276148C190283241 @default.
- W868276148 hasConceptScore W868276148C203014093 @default.
- W868276148 hasConceptScore W868276148C2776090121 @default.
- W868276148 hasConceptScore W868276148C31573885 @default.
- W868276148 hasConceptScore W868276148C502942594 @default.
- W868276148 hasConceptScore W868276148C53227056 @default.
- W868276148 hasConceptScore W868276148C55493867 @default.
- W868276148 hasConceptScore W868276148C71924100 @default.
- W868276148 hasConceptScore W868276148C86803240 @default.
- W868276148 hasConceptScore W868276148C8891405 @default.
- W868276148 hasConceptScore W868276148C98274493 @default.
- W868276148 hasConceptScore W868276148C98424977 @default.
- W868276148 hasIssue "21" @default.
- W868276148 hasLocation W8682761481 @default.
- W868276148 hasOpenAccess W868276148 @default.
- W868276148 hasPrimaryLocation W8682761481 @default.
- W868276148 hasRelatedWork W1970757709 @default.
- W868276148 hasRelatedWork W1985097300 @default.
- W868276148 hasRelatedWork W1992728515 @default.
- W868276148 hasRelatedWork W2054743528 @default.
- W868276148 hasRelatedWork W2071335106 @default.
- W868276148 hasRelatedWork W2079831187 @default.
- W868276148 hasRelatedWork W2252719556 @default.
- W868276148 hasRelatedWork W2353485240 @default.
- W868276148 hasRelatedWork W2739912350 @default.
- W868276148 hasRelatedWork W3140516708 @default.
- W868276148 hasVolume "124" @default.
- W868276148 isParatext "false" @default.
- W868276148 isRetracted "false" @default.
- W868276148 magId "868276148" @default.
- W868276148 workType "article" @default.